Health
FDA Approves First Treatment for MCT8 Deficiency, a Rare Genetic Disorder
Emcitate (tiratricol) gives families affected by Allan-Herndon-Dudley syndrome their first FDA-approved option.
Egetis Therapeutics News
All Happy News Company coverage of Egetis Therapeutics: the latest health news, with links to every original source.
Got good news? Let's share it.
Publish your impact story, donation, milestone or community launch on Happy News Company from $99. Nonprofits save 25%.